Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491121 | 0.90 | LRRK2 (0.37) | MEN1KMT2AMAPTPOLBMAPK1 | |
| SCHEMBL2191701 | 0.84 | TRPV1 (0.36) | MEN1KMT2ALRRK2MAPK3L3MBTL1 | |
| SCHEMBL4765655 | 0.79 | MEN1 (0.34) | MEN1KMT2AMAPTPOLBGAA | |
| SCHEMBL2190430 | 0.79 | EGFR (0.33) | MEN1KMT2AMAPTPOLBGAA | |
| SCHEMBL4503972 | 0.72 | LRRK2 (0.38) | MEN1KMT2AMAPTPOLBMAPK1 | |
| SCHEMBL5496929 | 0.72 | CRHR1 (0.40) | MEN1KMT2AMAPTPOLBMAPK1 | |
| SCHEMBL5496988 | 0.69 | SMO (0.36) | MEN1KMT2AMAPTPOLBGAA | |
| SCHEMBL4763543 | 0.68 | CACNA1B (0.35) | MAPTRXRANR4A2 | |
| SCHEMBL3277032 | 0.66 | GAA (0.39) | MEN1KMT2AMAPTPOLBMAPK1 | |
| SCHEMBL9024724 | 0.62 | GAA (0.46) | MEN1KMT2AMAPTPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462622-B2 | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1395591-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-04 | — | — | EP | disclosed |
| EP-1383747-B1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1395591-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1383747-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002100863-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002088095-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | MEN1 1506/4885KMT2A 4464/4885MAPT 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.